Freenome maps path forward for blood-based cancer screenings with $270M C round
Company expanding pivotal trial as it assesses next indications
Freenome plans to develop additional blood-based cancer tests as its lead product, an early detection colorectal cancer diagnostic, enters pivotal testing.
Freenome’s $270 million series C will fuel the company’s push to move its multiomics cancer screening technology beyond colorectal cancer.
New investor Bain Capital Life Sciences and existing investor Perceptive Advisors led the untranched round, which brings Freenome’s total private funding to more than $500 million.